Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A biomarker is a biological observation that substitutes for and ideally predicts a clinically relevant endpoint or intermediate outcome that is more difficult to observe. The use of clinical biomarkers is easier and less expensive than direct measurement of the final clinical endpoint, and biomarkers are usually measured over a shorter time span. They can be used in disease screening, diagnosis, characterization, and monitoring; as prognostic indicators; for developing individualized therapeutic interventions; for predicting and treating adverse drug reactions; for identifying cell types; and for pharmacodynamic and dose-response studies. To understand the value of a biomarker, it is necessary to know the pathophysiological relationship between the biomarker and the relevant clinical endpoint. Good biomarkers should be measurable with little or no variability, should have a sizeable signal to noise ratio, and should change promptly and reliably in response to changes in the condition or its therapy. © 2017 by John Wiley & Sons, Inc.

Original publication

DOI

10.1002/cpph.19

Type

Journal article

Journal

Curr protoc pharmacol

Publication Date

17/03/2017

Volume

76

Pages

9.23.1 - 9.23.17

Keywords

adverse drug reactions, biomarkers, diagnosis, drug development, drug discovery, monitoring drug therapy, screening, surrogate endpoints, surrogate markers, Biomarkers, Biomarkers, Pharmacological, Diagnosis, Dose-Response Relationship, Drug, Drug Discovery, Drug-Related Side Effects and Adverse Reactions, Humans, Pharmacokinetics, Sensitivity and Specificity, Signal-To-Noise Ratio, Terminology as Topic